Introduction
Malignant salivary gland carcinomas make up a rare subset of head and neck cancer. Despite having indolent clinical courses, more than 30% of salivary carcinomas eventually relapse distally, often to the lungs. 1 A smaller, but still significant, subset of patients with high-risk salivary carcinomas recur in the tumor bed or in regional lymph nodes. 1,2 Depending on disease characteristics, adjuvant radiotherapy is often indicated to decrease these recurrences. 3, 4 Salivary carcinoma recurrences are particularly challenging to treat because they may involve areas previously treated with surgery and radiation.
A third type of recurrence, skull base recurrence, has also been described for salivary gland carcinomas. Two of the histological subtypes of salivary carcinoma, adenoid cystic and squamous cell, have well known propensities to spread along perineural tracts. Tumor cells often track along major divisions of the facial and trigeminal nerves and follow their courses retrograde into the skull base. Depending on the population studied, the long-term rate of skull base metastases has been reported to be between 3 and 30%. [4] [5] [6] Although adenoid cystic tumors have the greatest rate of skull base recurrences, these recurrences have been reported from all histological types and sites of primary disease (parotid,
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Abstract
Background Approximately 3 to 13% of salivary carcinomas recur at the skull base. We report our experience treating these recurrences with stereotactic radiation. Methods In total, 14 patients with skull base recurrence of salivary gland carcinoma were identified. Patient characteristics, treatment parameters, response to treatment, local recurrence-free/overall survival, and patterns of failure were studied. Results All 12 symptomatic patients experienced palliation of symptoms. Two grade 3 toxicities were observed. Local recurrence-free survival after skull base treatment was 28 months (74 months after allowing for additional course of salvage radiotherapy). Overall survival was 153 months from primary diagnosis and 67 months from first skull base failure. Of 13 treatment failures, 8 occurred at margins; the rest were infield. All intracranial failures occurred along meningeal surfaces. Conclusions Stereotactic radiation provides well-tolerated palliation for the majority of patients, but with a high rate of local failure. Due to the propensity for meningeal failures, we suggest increasing margins along the meningeal surfaces when treating these patients. submandibular, or minor glands). Skull base recurrences can lead to a variety of neurological symptoms, including pain and visual changes. Patients with skull base recurrences also have a poor prognosis.
5
Recent retrospective series have reported the results of stereotactic radiation with or without surgery in an attempt to treat these recurrent tumors. These studies report good short-term palliation of symptoms, but the long-term outcomes and patterns of failure remain unclear. Here we report on a series of patients treated for skull base recurrences of salivary gland cancer at our institution with stereotactic radiation. We include results on characteristics of patients with skull base recurrence, treatment response and toxicities, local control and survival after treatment, and patterns of failure.
Materials and Methods

Patient Record Review
The records of all patients treated at Loyola University Medical Center with stereotactic radiation to the skull base between 1995 and 2013 were reviewed after obtaining institutional review board approval. Of these patients, 14 were identified with salivary carcinoma as the primary disease. Demographic data and initial disease characteristics including tumor site, stage, and histology, as characterized by initial pathology review at Loyola or the referring hospital, were obtained. Additionally, the treatment for the primary disease was recorded.
Patient Evaluation
All patients were examined by a surgeon and radiation oncologist prior to treatment. Symptoms reported during initial evaluation and radiographic data including magnetic resonance imaging (MRI) of the head/neck were reviewed to characterize the location and size of the lesion.
The radiation dose fractionation method was decided upon on the basis of lesion size and proximity to critical structures such as optic chiasm and cranial nerves, taking into account the low tolerance of these structures for single fraction radiosurgery.
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Patient Follow-Up
After treatment, patients were followed with interval MRIs and physical examinations until the end of follow-up for this study (August 31, 2014) or patient death. Symptomatic responses were noted. Maximal radiographic responses were characterized as complete response (no evidence of lesion), partial response (interval decrease in lesion), or stable (no appreciable change). Radiographic recurrences were recorded on the basis of interval increase in lesion size (infield failure) or presence of a new adjacent (marginal failure) or distant lesion. All sites of metastases and causes of death were tracked. Significant treatment-related toxicities were also recorded for each patient.
Statistical Methods
Local recurrence-free survival was calculated from time of diagnosis of a skull base lesion to time of evidence of radiographic disease progression. Survival times since diagnosis of the primary cancer and since first skull base metastasis were also recorded. Kaplan-Meier estimates for median survival are reported. Local recurrence-free survival times were censored at death or last follow-up. Overall survival and survival since first skull base metastasis were censored at last follow-up.
Results
Patient Characteristics
Patient demographics and the characteristics of their primary disease are shown in ►Table 1.
Of 14 patients, 12 were treated with adjuvant radiation for their primary disease with doses of 50.4 to 66 Gy in 1.8 to 2.0 Gy/fraction. The remaining two patients treated without radiation had early stage disease and were treated with wide local excision alone. The number of patients whose adjuvant radiation fields covered the skull base could not be determined.
A total of 21 lesions (including skull base treatment failures) were treated. Three patients underwent subtotal resection of their skull base disease prior to referral for radiation therapy of remaining gross disease. All patients except for one had a single skull base lesion at first treatment. These lesions are characterized in ►Table 2, with data involving time since initial diagnosis, location of lesion, and symptoms. The median duration between diagnosis of primary disease and time of treatment of first skull base metastatic lesion was 55 months (range: 13-248 months).
Treatment
All patients were treated with stereotactic localization. For patients treated with stereotactic radiosurgery (SRS; n ¼ 6 lesions), frame-based localization was employed. These patients were treated with either the Radionics XKnife system (Integra LifeSciences, Plainsboro, NJ) or Novalis Radiosurgery platform (BrainLab Inc., Westchester, IL). After a frame was placed by a neurosurgeon under local anesthesia, a computed tomographic scan with 1.5 mm thickness was obtained for localization and fused with MRI scans (T1, with and without contrast, and T2). The single patient treated with the Radionics XKnife system was treated with 15 Gy to the 50% isodose volume. The other patients were treated with 15 to 22 Gy to 58 to 98% isodose volume using the BrainLab RT (Munich, Germany) planning software. After radiosurgery, all patients were observed for 1 to 2 hours prior to discharge. Dexamethasone, 20 mg, was given on the treatment day and patients were discharged home on an approximate 2-week taper.
The lesions treated with fractionated SRS (n ¼ 5) were treated with 25 Gy in five fractions to approximately 85% isodose volume. The remaining lesions were treated with fractionated stereotactic radiotherapy (FSRT; n ¼ 10), 45 to 66 Gy in 1.8 to 2.0 Gy/fraction (►Table 2). One of these patients also had a sequential SRS boost. Both of these sets of patients were treated with mask-based immobilization/ localization on a linear accelerator system with the aforementioned software planning system.
Follow-Up
All patients were followed up until death or until the time of last data collection for this study, with no patients lost to follow-up. Median follow-up after radiotherapy treatment for first skull base lesion was 26.2 months (range: 6.3-75.4 months).
Treatment Response
Of the 14 patients treated, 12 presented with neurological symptoms during the course of their disease, most commonly pain and diplopia. All patients who presented with symptoms experienced symptom palliation (►Table 2). Radiographically, five lesions showed complete response, six lesions showed partial response, five lesions were stable, and the remainder (five lesions) could not be assessed. There were two grade 3þ toxicities, radiation necrosis for patient 9 (►Table 2) and possible contribution to meningitis in patient 3 (►Table 3).
Survival
The median local recurrence-free survival for lesions was estimated to be 28 months (95% confidence interval [CI]: 5-51 months) for initial treatment; allowing for salvage, this was extended to 74 months (7-141 months; ►Fig. 1). Allowing for salvage, 7 of the 14 patients were locally controlled until death or last follow-up. The median overall survival since primary diagnosis was estimated at 153 months (95% CI: 27-280 months; ►Fig. 2a), and survival since first skull base metastasis was estimated to be 67 months (95% CI: 0-159 months; ►Fig. 2b). The cause of death was determined to be neurological progression in at least three patients (►Table 3).
Patterns of Failure
As shown in ►Table 2, there were 13 local treatment failures, 8 of which failed at the margin (remaining were infield failures). An example of marginal failure is shown in ►Fig. 3. Upon radiographic review, all intracranial marginal failures occurred along the meningeal axes, that is, there were no failures by intraparenchymal extension. Distant metastases and cause of death for each patient are noted in ►Table 3.
Discussion
To our knowledge, this series represents the largest reported series of patients with skull base recurrences from salivary carcinoma primaries treated with radiation. The patients in our series generally had appropriate therapy for their primary disease. However, we could not verify the specific adjuvant radiation therapy parameters for some of our patients due to incomplete records. Specifically, we would have liked to ascertain how many of our patients had radiation fields extending into skull base during primary treatment as this may have predictive significance for skull base recurrences.
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The most common initial presentation (mode) in our series was a patient with advanced left parotid adenoid cystic carcinoma, a finding that agrees with other reports on salivary cancer. However, several patients had early stage disease (and therefore were not offered radiation or even total parotidectomy) that eventually recurred at the skull base. There were also a wide range of histologies observed (adenoid cystic, acinic cell, adenocarcinoma, ductal carcinoma, and mucoepidermoid). Our results show that stereotactic radiation effectively palliates patient symptoms, whether single-fraction SRS, multifraction SRT, or conventional FSRT is used. This high palliation rate is in agreement with prior studies showing effective palliation with Gamma Knife radiosurgery (Elekta, Stockholm, Sweden). 8, 9 From a patient comfort viewpoint, which is of increased importance in a palliative setting, a hypofractionated SRT approach may be most suitable as it avoids both placement of a headframe and repeated trips to the treatment facility. We observed a 65% radiographic response rate (complete or partial reported in the adenoid cystic carcinoma series by Mori et al.
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In our study, there were patients within all the three treatment group types who eventually failed locally, and we did not have enough statistical power to discriminate between the three fractionation schedules. One area of concern from our results is the large rate of marginal failures along meningeal surfaces after stereotactic radiation, a finding that has not been previously reported. Past series have not been clear as to whether the local failures were true in field failures or marginal recurrences. Highly conformal stereotactic radiation may prevent toxicity to critical structures located in the skull base and allow for shorter fractionation schedules for similar doses. However, given our finding, extending the radiation field to include a "high-risk clinical target volume" by expanding into the meningeal surfaces may be appropriate. A possible hypothesis for this pattern of failure is that the purported mechanism for perineural invasion/spread 10 is mimicked in meningeal spread. In addition to marginal failures, we also observed two cases of "skip" lesions along the meninges, with one of these patients having leptomeningeal involvement in the spinal cord (►Table 2, patients 1 and 2). These skip lesions contributed to mortality in at least one of our patients and may correlate with the deaths from "distant intracranial disease" reported by Mori et al. 9 Since infield failures were approximately one-third of all local failures in this study, dose de-escalation is not a viable option for these patients. In our series, as in the prior series, salvage re-irradiation seemed to be an effective treatment for local failure. Salvage therapy palliated new symptoms with acceptable toxicity and added a median of 46 months of local control. While the series by Lee advocate serial imaging during follow up to catch early marginal failures, as offering salvage therapy may be of benefit even to asymptomatic patients. Toxicity from treatment tended to be low in our study, which agrees with the current literature. One patient who received three treatments (one for initial disease and then subsequently two salvage treatments) experienced symptomatic brain necrosis, causing seizure activity. Another patient who underwent both partial resection and stereotactic radiation developed meningitis after a cerebrospinal fluid leak and succumbed to this complication (►Table 3, patient 3). Otherwise, patients tolerated the treatment without major adverse events.
In conclusion, this study suggests that the majority of patients who have skull base recurrences will be effectively palliated by radiation, but will often fail after first therapy, and may even succumb from neurological disease. In addition, we observe that survival following skull base recurrences may be greater than the local control at the skull base, suggesting that managing skull base recurrences following salivary cancer is not a trivial undertaking. Our study shows a unique pattern of failure along the meningeal surfaces after stereotactic skull base radiation for salivary gland cancer recurrence, suggesting that larger treatment fields or larger margins along the meningeal surfaces may be worth studying. Our results also confirm the importance of long-term follow-up in patients with salivary gland carcinoma.
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